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Accumulating evidence supports the notion that high-dose (>5Gy) radiotherapy (RT)
regimens are triggering stronger pro-immunogenic effects than standard low-dose (2Gy)
regimens. However, the effects of RT on certain immunoregulatory elements in tumors
remain unexplored. In this study, we have investigated the effects of high-dose radio-
therapy (HD-RT) on the immunomodulating functions of cancer-associated fibroblasts
(CAFs). Primary CAF cultures were established from lung cancer specimens derived from
patients diagnosed for non-small cell lung cancer. Irradiated and non-irradiated CAFs
were examined for immunomodulation in experiments with peripheral blood mononuclear
cells from random, healthy donors. Regulation of lymphocytes behavior was checked
by lymphocyte proliferation assays, lymphocyte migration assays, and T-cell cytokine
production. Additionally, CAF-secreted immunoregulatory factors were studied by multi-
plex protein arrays, ELISAs, and by LC-MS/MS proteomics. In all functional assays, we
observed a powerful immunosuppressive effect exerted by CAF-conditioned medium on
activated T-cells (p>0.001), and this effect was sustained after a single radiation dose
of 18Gy. Relevant immunosuppressive molecules such as prostaglandin E2, interleukin-
6, and -10, or transforming growth factor-β were found in CAF-conditioned medium, but
their secretion was unchanged after irradiation. Finally, immunogenic cell death responses
in CAFs were studied by exploring the release of high motility group box-1 and ATP.
Both alarmins remained undetectable before and after irradiation. In conclusion, CAFs
play a powerful immunosuppressive effect over activated T-cells, and this effect remains
unchanged after HD-RT. Importantly, CAFs do not switch on immunogenic cell death
responses after exposure to HD-RT.
Keywords: cancer-associated fibroblasts, high-dose radiation, lung cancer, tumor immunology, immunogenic cell
death
Introduction
During the last decade, clinical implementation of high-dose radiotherapy (HD-RT) has revolu-
tionized the therapeutic outcome for treatment-resistant cancers like non-small cell lung carcinoma
(NSCLC). In the clinics, oligo-fractionated HD-RT regimens are often associated with stereotactic
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body radiotherapy (SBRT) or stereotactic ablative body
radiotherapy (SABR) (1–3). Minimal margins of normal tissue in
the irradiated field combined with high-precision image-guided
dose-delivery and steep dose-gradients constitute the fundament
for increasing dose per fraction above the conventional 2Gy while
ensuring acceptable toxicity. An understanding of the biological
consequences to HD-RT in a heterotypic cellular context is still
in its infancy (4), but a thorough elucidation holds the promise of
optimized and refined treatment strategies in the clinics (5).
On the ground that clinical RT is affecting a well-defined vol-
ume of heterotypic tumor tissue – and questioning the dogma that
direct DNA damage to neoplastic cells is the sole mechanism for
tumor control mediated by RT – researchers have instigated stud-
ies of radio-responses in different tumor compartments including
both epithelial tumor cells and tumor-associated stromal cells.
At present, radio-responses in the diverse population of stromal
immune cells are probably the best explored of the non-malignant
cells (6).
From an immunological point-of-view, the clinical success
of HD-RT has been crucial for revitalizing the idea of using
RT as an immunological adjuvant to improve clinical outcome
(7–10). Recent findings have generated enthusiasm toward the
assumption that RT and immunotherapy in combination may
induce so-called abscopal off-target responses which in turn could
improve not only local, but also distant, tumor control (11–14)
The ambitious goal of optimizing RT-induced systemic immune-
responses demands scientific efforts toward fine-tuning radiation-
dose and regimens (15, 16). Several reports have already indicated
that HD-RT, rather than low-dose (LD)-RT, are inducing stronger
pro-immunogenic responses (17–19). Interestingly, recent exper-
iments in mammary carcinoma cells indicate that RT indeed
provokes a dose-dependent enhancement of immunogenic cell
death (ICD) (20). However, it is still an open question whether
RT-induction of ICD in tumor cells alone is sufficient for turn-
ing a typical immunosuppressive microenvironment into a pro-
immunogenic milieu capable of initiating a systemic response.
Cancer-associated fibroblasts (CAFs) are considered one of
the major cellular components of the tumor microenvironment
(21, 22), and high numbers of infiltrating CAFs in the tumor
tissue are generally associated with poor prognosis and treat-
ment outcome (23, 24). In contrast to normal tissue fibroblasts,
CAFs are contributing to cancer progression, essentially by the
secretion of a long array of soluble paracrine factors; i.e., growth
factors, cytokines, and chemokines that on one hand regulate
the behavior of adjacent cancer cells (25, 26) but also mediate
recruitment of inflammatory and immune cells (27), as well as
bone-marrow derived progenitor cells (28, 29). However, the role
of CAFs as key inflammatory and sentinel cells of the immune
system is less known (30–32). In fact, through cytokine and
chemokine secretion, stromal fibroblasts are efficiently mediating
local immunomodulation of the tumor tissue, by directly affecting
trafficking, state of differentiation and activation of the broad
population of immune cells. Among other observed effects, CAFs
may influence T-regulatory cells functionality by production of
PGE2 (33), and can impair Th1 differentiation, CTL activation,
or DC maturation by production of TGF-β (34). Moreover, some
recent reports highlight the indirect effects of CAFs on immune
cell infiltration and function (35), consisting of regulation of
angiogenesis, lymph-angiogenesis, hypoxia, extracellular matrix
remodeling, and metabolism.
Ionizing radiation in a therapeutic setting affects concomitantly
non-malignant as well as malignant tumor cells (36), thus provok-
ing also tumor cell-extrinsic responses to treatment (8, 37–39).
Hence, as one of the main cellular components of the tumor mass,
CAFs are receiving the prescribed radiation dose in full during
RT treatment, and the consequential biological effects of the treat-
ment are dependent on radiation dose and fractionation (4). Of
note, a single high radiation dose (18Gy) is inducing permanent
DNA damage responses in CAFs, accompanied with development
of irreversible cellular senescence (40). Moreover, same radiation
dose is able to influence the secretory profile of CAFs, thus affect-
ing paracrine communication by CAFs (41). Herein, we shed light
on the effects of radiation on the immunoregulatory properties
exerted by CAFs.
Materials and Methods
Patients and Specimens
Lung tumor specimens were obtained from seven randomly
selected patients diagnosed with NSCLC and operated at the Uni-
versityHospital ofNorthernNorway. Tumor and donor character-
istics are outlined in Table 1. Average age of patients included in
the study was 61 years, and none of the patients were undergoing
other therapy than surgery when their samples were collected.
Peripheral blood samples were obtained from healthy donors
attending the University Hospital of Northern Norway Blood
Bank. Samples were anonymously coded and a written informed
consent was obtained from all patients and healthy volunteers in
accordance with the Declaration of Helsinki. The study has been
approved by the Regional Ethical Committee (REK-Nord).
CAF Isolation, Characterization and Cultures
Human lung CAFs were harvested from freshly resected NSCLC
tumor tissues from lung cancer patients. After surgical resection,
tumor specimens were processed following a previously described
protocol (40). Briefly, tumor tissues were mechanically minced
into small pieces (1–1.5mm3), followed by enzymatic digestion
for 1.5 h at 37°C in 10ml of Dulbecco’s modified Eagle’s medium
TABLE 1 | Donor features corresponding to the source of CAFs used for
experimentation in this study.
Number Age Sex Tumor type T-size
(mm)
T-stage
and N-stage
Donor 1 60 F MD-SCC 35 pT2aN0
Donor 2 67 F MD-SCC 30 pT1bN0
Donor 3 62 F BAA 12 pT1aN0
Donor 4 57 F MD-AC 30 pT2aN1
Donor 5 64 F LD-AC 30 pT1bN0
Donor 6 58 M MD-AC 60 pT2bN0
Donor 7 60 F BAA 6 pT1aN0
BAA, bronchio-alveolar adenocarcinoma; AC, adenocarcinoma; SCC, squamous cell
carcinoma; LCC, large cell carcinoma; M, male; F, female; HD, highly differentiated, MD,
middle differentiated; LD, low differentiated.
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(DMEM) containing bacterial collagenase (Cat.# C-9407 Sigma-
Aldrich, St Louis, MO, USA) at a final concentration of 0.8mg/ml.
Digested tissue was spun down to eliminate collagenase, and
resuspended in fresh growth medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) (Cat. # S0115 Biochrom,
Berlin, Germany). Pure fibroblast cultures were obtained by selec-
tive cell detachment from the primary culturemix, using Enzyme-
free cell detachment solution (Cat. # S-014-B EMD Millipore,
Norway) and continued cell propagation in the presence of 10%
FBS. Cells were grown at 3% oxygen for a short culture period
(until passage two). Resulting cell cultures were characterized
for purity and cell identity by flow cytometry using fluoroscein
isothiocyanate (FITC)-conjugated anti-human α-smooth muscle
α-actin antibody (Cat. # ab8211 Abcam, Cambridge, UK), and
by immunofluorescent staining with anti-human fibroblasts acti-
vation protein (FAP) antibody (Cat. # ab53066 Abcam, Cam-
bridge, UK) on formalin-fixed CAF-cultures (40). Immediately
after determining purity, cells were harvested, counted, and cry-
opreserved in DMEM (Cat. # D6046 Sigma-Aldrich, St Louis,
MO, USA) with 10%Dimethyl sulfoxide (DMSO) and 20% FBS at
5 105 cells per cryotube until analysis. Before experimentation,
cells were thawed in complete medium consisting of DMEMwith
10% FBS and 1% penicillin-streptomycin (Cat. # P0781 Sigma-
Aldrich, St Louis, MO, USA) and seeded in T-75 culture flasks.
Preparation of CAF Conditioned Medium
At the third passage, CAFs were seeded at 4 105 cells per T-
75 tissue culture flasks and incubated 24 h (at 37°C) for attach-
ment. After initial cell attachment and spreading, cultures were
washed with PBS and new medium (6ml) was replaced and
cultures irradiated (1 18Gy), as previously described (40). Con-
ditioned medium (CM) from irradiated and control CAFs were
collected between days 3 and 6 post-irradiation. Cell-density was
4 105 cells/ml at the time ofmedia collection. Supernatants were
spun down by centrifugation at 2200g for 5min and then fil-
trated through a 0.45 µm filter for elimination of contaminant
cell bodies. The resulting conditioned medium was either used
immediately for experimental analysis or frozen at  80°C for
further analysis.
Isolation and Culturing of Human PBMCs
Peripheral bloodmononuclear cells (PBMCs) fromhealthy volun-
teers were isolated using a Lymphoprep™ density gradient (Cat.
#1115754 Axis-Shield, Oslo, Norway), and following standard
procedures. Briefly, peripheral blood was diluted (1:1) in PBS and
layered over a Lymphoprep™ gradient, followed by 30min of cen-
trifugation at 700g at room temperature and without breaks. To
remove platelets fromperipheral blood, PBMCs from the resulting
gradient-interface were collected using a Pasteur pipette, washed
three times with 40ml of 0.2% PBSA (0.2% bovine serum albumin
in PBS), and spundown at 350g for 10min at room temperature.
Purified PBMCs were counted and frozen down in 90% FBS
with 10% DMSO at 5 107 cells per cryotube. Before analysis,
PBMCs were thawed in complete medium consisting of Iscove
modified Dulbecco medium (IMDM) (Cat. # BE12-722F Lonza
FWO-Vlaanderen, Belgium) with 10% FBS and 1% penicillin-
streptomycin, and cultured in T-75 culture flasks at 37°C, in a 7.5%
CO2 humidified atmosphere.
Lymphocyte Proliferation Assays
Rates of T-cell proliferation were assessed using the carboxyfluo-
rescein succinimidyl ester (CFSE) dilution assay. Cultured PBMCs
were washed in PBS by centrifugation at 400g for 4min, and
resuspended in 0.5ml of PBSA (0.2%) and CFSE (Cat. # C34554
Molecular Probes, Life technologies, CA, USA) at 5 µg/ml, fol-
lowed by incubation at 37°C for 15min, and immediate cooling on
wet ice and dilution in 10ml of cold IMDM. In coculture exper-
iments, irradiated and non-irradiated CAF cultures were estab-
lished in 24-well plates, and CFSE-labeled PBMCs were added at
a density of 106 live cells per well. Immediately after initiation
of cocultures, cells were exposed to the mitogen phytohemagglu-
tinin (PHA) (1 µg/ml) (Cat. # 1249738 Roche, Penzberg, Upper
Bavaria, Germany). Mixed cultures were incubated for 5–6 days at
37°C, with 50%medium replacement on day 3. Similar procedures
were carried out for experiments with CAF-CM, but instead of
cells, CAF-CM was diluted (1:1) with fresh pre-warmed lympho-
cyte growth medium. Following incubations, PBMCs were har-
vested, centrifuged at 400g for 4min, and resuspended in 0.5ml
PBS. CFSE fluorescence was analyzed on a FACSCalibur™(Becton
Dickinson) flow cytometer, and flow cytometric data were ana-
lyzed by FlowJo (TreeStar, Ashland, OR, USA) software.
Multiplex Protein Arrays (Luminex)
Quantitative measurements of cytokines and inflammatory fac-
tors released into the culture medium were performed using a
suspension array technique. Supernatants from CAFs, PBMCs,
or cocultures were prepared as previously described, thawed and
analysed using a human cytokine 10 Plex panel kit (Cat. # LHC001
Invitrogen, Life technologies, Frederick, MD, USA) according
to the manufacturer’s protocol. All samples were analyzed in
duplicates and in dilutions of 1:4. Levels of proteins included in
the array were detected using the Bio-Plex® 200 system (Bio-
Rad laboratories, CA, USA), according to instructions from the
manufacturer. Data were processed using Bio-Plex Manager™ 6.0
Software (BIO-RAD, CA, USA).
Quantitative Protein Measurements by ELISA
Concentrations of PGE2 (Cat. # 500141 Cayman Chemical, Ann
Arbor, MI, USA), TGF-β (Cat. # DY240-05 R&D Systems, Min-
neapolis, MN, USA), and indoleamine 2,3-dioxygenase (IDO)
(Cat. # SEB547 Mu Cloud-clone corp., Houston, TX, USA) in
the conditioned media from irradiated and non-irradiated CAFs,
prepared as described above, were determined using ELISA kits
according to the manufacturer’s instructions.
Mass Spectrometry-Based Proteomics
Cancer-associated fibroblasts conditioned medium from irradi-
ated and non-irradiated cells were collected between days 3 and
6 post-treatment, concentrated in VIVASPIN centrifuge tubes
(3000MW cutoff) (Cat. # Vs0612 Startorius Stedim, Goettingen,
Germany) by spinning at 2200g for 30min, and run in 1D
SDS–PAGE to clean samples from salts and other non-protein
solutes. Upon staining of gels with Coomassie Blue, the entire
band spectrum was excised into three gel fractions. After exci-
sion, gel bands were subjected to in-gel reduction, alkylation, and
digestion using 2–10 ng/µl trypsin (V511A; Promega, Madison,
Frontiers in Oncology | www.frontiersin.org May 2015 | Volume 5 | Article 873
Gorchs et al. Immunomodulating functions by irradiated CAFs
WI, USA) (41). OMIX C18 tips (Varian, Inc., Palo Alto, CA,
USA) were used for sample cleanup and concentration. Peptide
mixtures containing 0.1% formic acid were loaded onto a Thermo
Fisher Scientific EASY-nLC1000 system and EASY-Spray column
(C18, 2 µm, 100Å, 50 µm, 15 cm). Peptides were fractionated
using a 2–100% acetonitrile gradient in 0.1% formic acid over
50min at a flow rate of 250 nl/min. Separated peptides were
analyzed using a Thermo Scientific Q-Exactive mass spectrom-
eter. Data were collected in data dependent mode using a Top10
method.
Raw data were analyzed by the MaxQuant (version 1.5.0.30)
and the Proteome Discoverer 1.4 software. Fragmentation spectra
were searched against the SwissProt (version 2011_12) database
using an in-house Mascot server (Matrix Sciences, UK). Peptide
mass tolerances used in the search were 10 ppm, and fragment
mass tolerance was 0.02Da. Peptide ions were filtered using a false
discovery rate (FDR) set to 1% for peptide identifications. Pro-
tein identities in the MaxQuant software were determined using
the Andromeda module, and by searching against the Uniprot
Human database. Label-free protein quantification (LFQ) was
also executed with the MaxQuant software. The generated list
of proteins resulting from the MaxQuant software was filtered
for contaminants and reverse hits in Perseus. Logarithms (log2)
of the LFQ intensities were calculated, and average values for
irradiated (n= 6) and control (n= 6) samples were presented
with SD. Proteins appearing with less than six measurements
were discarded.
Migration Assays
Chemotactic responses of activated lymphocytes were measured
by a Boyden chamber assay. Briefly, PBMCs dissolved in growth
medium were activated with PHA 24 h prior to starting the assay,
and then 100 µl of cell suspension (containing 1 106 cells) was
added on the top chamber of Transwell culture inserts (6.5mm
diameter, 8 µm pores, Cat. # CLS3464, Sigma-Aldrich, St. Louis,
MO, USA). Bottom chambers were filled with 600 µl of fresh
fibroblast growth medium or with CM from irradiated and non-
irradiated CAF cultures, in the presence or absence of SDF-1
(50 ng/ml) (Cat. # 300-28APeProTech,Oak Park, CA,USA). After
2 h, all PBMCs invading the lower chamber were harvested, cen-
trifuged at 400g for 4min, resuspended in 0.5ml of PBSA, and
counted with FACSCalibur™(Becton Dickinson) flow cytometer
for 60 s at high flow rate. The lymphocyte population was gated
on the forward and side scatter.
ATP Release Assay
Extracellular release of ATP from non-irradiated (0Gy) and irra-
diated CAFs (1 18Gy) was measured at different time points,
using the luciferin-based ENLITEN ATP assay (Cat. # FF2000
Promega, Madison, USA). Briefly, CAFs of two randomly selected
donors were seeded in duplicate per time point, with density of
40,000 cells per well in a 24-well plate, and kept at 37°C. Super-
natants were collected at 1, 6, and 24 h post-irradiation and cen-
trifuged at 2200g for 5min. ATP-driven bioluminescence was
assesed on a luminometer microplate reader (Labsystems Lumi-
noskan). A positive control was prepared by lysing unirradiated
CAFs with 0.1% Triton X-100 for 10min.
HMGB-1 Detection by Western Blotting
Cancer-associated-fibroblast-supernatant HMGB-1 levels from
irradiated and non-irradiated cultures, prepared as previously
described, were analyzed by Western blotting at different time
points. CAF-CM was collected 1, 6, 24, and 120 h after irradia-
tion and concentrated using VIVASPIN centrifugation tubes (Cat.
#Vs0612 Startorius Stedim Goettingen, Germany). Samples were
then boiled in a reducingNuPAGELDS sample buffer, resolved on
NuPAGE Novex 4–12% Bis–Tris gels, and electrotransferred onto
a polyvinylidene difluoride (PVDF) membrane (Millipore, Nor-
way). Membranes were hybridized with anti-HMGB1 antibody
(rabbit polyclonal to HMGB1-ChIP grade, Abcam, UK), followed
by HRP-conjugated secondary antibody labeling (goat polyclonal
anti-rabbit IgG, Abcam, UK). Reactions were developed by the
Western Blotting Luminol reagent (sc-2048; Santa Cruz Biotech-
nology, USA) according to the manufacturer’s instructions. Cell
lysates were collected in a Mastermix containing a 2 NuPAGE
LDS Sample buffer (Invitrogen, Norway), and a 1 NuPAGE
Sample Reducing Agent (Invitrogen, Norway) was used as a posi-
tive control.
Statistical Analysis
Values are expressed as means with SEM or SD as indicated. In
Multiplex protein arrays and ELISAs, only readings above the
detection limit of the assay are represented in figures. Data were
analyzed using paired Student’s t-test, and p-values<0.05 denoted
the presence of statistically significant differences. All statistics
were determined with Graph pad prism version 5.00 forWindows
(Graphpad).
Results
Prominent immunosuppressive abilities from CAFs have been
suggested in previous studies performed in immunocompetent
animal models (32). Based on this premise, we initially checked
whether we could reproduce such effects in functional assays
in vitro, and whether HD-RT affects in some way the potential
immunoregulatory functions of CAFs. To this end, we performed
T-cell proliferation assays comprising PHA-activated lympho-
cytes in coculture with irradiated (iCAFs) or non-irradiated
CAFs (Figure 1). Indeed, CAFs exerted a potent immunosup-
pressive effect on proliferating T-cells in a donor-independent
manner, and this effect was similar between irradiated and non-
irradiated CAFs.
Several reports have suggested that the immunoregulatory
properties of CAFs are mediated via the release of soluble factors
that directly or indirectly affect lymphocyte activation and/or
recruitment (35, 42). We thus explored if the same immuno-
suppressive effects observed during CAFs-lymphocytes cocul-
tures could be reproduced by using only the CM (Figure 2).
Results showed that the inhibitory effect was indeed mediated
via paracrine signaling, since similar effects could be reproduced
by CAF-CM, and almost identical outcomes were observed with
both irradiated and non-irradiated cells. Of importance, in these
experiments we were checking also whether low-dose fraction-
ated radiation had same or different outcomes as compared with
high-dose radiation. In fact, immunosuppressive effects remained
unperturbed under both radiation regimens.
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FIGURE 1 | T-cell proliferation assays: immunosuppressive effects
elicited by irradiated and control CAFs during coculture. T-cell proliferation
assays were performed using CellTrace™ CFSE labeled human PBMCs
activated with 1 µg/ml PHA. Cells were cocultured with irradiated (iCAF-CC) or
non-irradiated CAFs (CAF-CC) at a ratio of 1:100 CAF:PBMC and allowed to
proliferate for 5 days. Assays were performed with CAFs isolated from five
randomly selected donors. T-cell proliferation was determined by measuring
CFSE fluorescence intensity by flow cytometry after gating the lymphocyte
population by forward and side scatter. (A) Representative flow cytometry dot
plots showing percentage of CFSElow-labeled T-cells. One out of five
representative experiments is shown. (B) Graph shows rate of T-cell proliferation
determined by loss of CFSE fluorescence. Data points are representative for five
different CAFs donors with bars representing means from triplicate experiments.
Student’s t-test value (*p<0.05).
To further explore the immunosuppressive functions of CAFs
and iCAFs, we checked the expression of effector cytokines by
activated T-cells exposed to CAF-CM (Figure 3). In line with our
initial observations, culture supernatants of both irradiated and
non-irradiated CAFs were able to efficiently inhibit secretion of
the immunoregulators IFN-γ andTNF-α in a similar way. Of note,
neither IFN-γ nor TNF-α could be detected in supernatants of
CAFs or iCAFs.
To our knowledge, CAF-mediated effects on lymphocyte
migratory functions have not been studied previously. Given
the striking suppressive actions achieved with CAF-CM on
T-cell activation, we checked whether supernatants from CAFs
and iCAFs could influence the migratory abilities of lympho-
cytes in Transwell insert systems (Figure 4). The effects were
checked in the presence or absence of the potent leukocyte
chemoattractant stromal-derived factor 1 (SDF-1). In line with
the preceding findings, supernatants from CAFs and iCAFs
could equally block migration of lymphocytes exposed to SDF-
1. Of importance, this effect could only be reproduced if the
lymphocytes were pre-activated with PHA before the migration
assay.
To deepen our understanding on the potential CAF-derived
soluble mediators behind the observed effects, we quantified the
expression of acknowledged immunosuppressivemolecules in the
culture medium from CAFs and iCAFs by immunobased assays
(Figure 5). Anti-inflammatory molecules such as interleukin
(IL)-10 or IDO were not detected in CAF supernatants; how-
ever, other important immunoregulators such as IL-4, TGF-β, or
PGE2 were detected in the culture medium, but at relatively low
levels. The results show approximately same amounts of all three
factors in supernatants from both irradiated and non-irradiated
cells.
Our study of CAF-derived soluble signals with immunoreg-
ulatory potential was then broadened by applying LC-MS/MS
proteomics on concentrated cell culture supernatants. Protein
identification and classification was achieved through computa-
tional analysis, including bioinformatics and systems biological
interpretation of results. Biological pathways and protein func-
tions including cell communication, immunosystem processing,
and secretion were annotated by Gene Ontology Biological Pro-
cess in Perseus. Proteomic analyses of the secretome from the
six donors gave a total yield of 978 identified proteins, of which
261 had relevant inflammatory or immunomodulatory functions.
Full list of identified proteins from each donor is included in
the Table S1 in Supplementary Material. From the last men-
tioned group, a selection of 35 immunoregulatory proteins, which
could be quantified in supernatants from at least two of the
donors, was further used for comparative analyses. LFQ intensities
of each protein were calculated by the MaxQant software, and
average expression values from all six donors were determined.
As shown in Figure 6; no significant changes were observed
between controls and irradiated cells in any of the 35 selected
proteins.
HD-RT has been shown to enhance ICD responses in dif-
ferent types of cancers (20). Given the increasing attention put
on ICD responses exerted by radiotherapy (43), we aimed at
addressing whether also CAFs turn on ICD mechanisms after
exposure to high-dose irradiation. ICD is characterized by the
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FIGURE 2 | T-cell proliferation assays: immunosuppressive effects
elicited by irradiated and control CAF-CM. T-cell proliferation assays
were performed using CellTrace™ CFSE labeled human PBMCs activated
with 1 µg/ml PHA and cultured with CAF-CM at a 1:1 ratio for 5 days.
Assays were performed with CM harvested 3 days post-RT from irradiated
(iCAF-CM) or non-irradiated (CAF-CM) CAFs cultures. T-cell proliferation
was determined by measuring the CFSE fluorescence intensity by flow
cytometry after gating the lymphocytes population by forward and side
scatter. (A) Representative flow cytometry dot plots showing the
percentage of CFSElow-labeled T-cells. One out of three representative
determinations is shown. (B) Graph shows the rate of T-cell proliferation
determined by CFSE fluorescence loss. Data points are representative for
three different CAF donors with bars representing means from triplicate
determinations. Student’s t-test value (**p<0.001).
release of danger signals or alarmins from damaged or dying cells,
including molecules such as ATP and high motility group box-
1 (HMGB-1) (44). We thus explored the presence of ATP and
HMGB-1 in the culture medium from CAFs collected at different
time points post-irradiation (1 18Gy) (Figure 7). Our results
clearly demonstrate that CAFs do not turn on ICD mechanism
after exposure to HD-RT, as neither ATP nor HMGB-1 could be
detected in the conditioned medium.
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FIGURE 3 | Inhibition of T-cell derived immunogenic cytokines secretion
by conditioned medium from irradiated and control CAFs. Quantitative
levels of (A) IFN-γ and (B) TNF-α were measured by multiplex cytokine
immune-assays in the supernatants of T-cell cultures. Experimental groups
include PBMCs in regular growth medium or PBMCs in CM obtained from
irradiated (iCAF-CM) and non-irradiated (CAF-CM) CAF cultures. Data represent
meanSD of five different CAF donors from triplicate experiments. Student’s
t-test value (***p<0.0001). ND; non-detected.
FIGURE 4 | CAF-CM from irradiated and non-irradiated cultures
inhibits the migratory capacity of activated lymphocytes.
(A) Experimental setup for lymphocyte migration assays using
polycarbonate filter chambers with 8 µm pore size. PBMCs (106), activated
24 h prior to assaying, were added to the upper chambers while the lower
chambers contained growth medium or conditioned medium with or
without SDF-1. The assay was run for 2 h at 37°C and cells migrating to
the lower chambers were quantified using flow cytometry with appropriate
lymphocyte gating. (B) Relative migration rates, corresponding to
percentages of migrating cells expressed in relation to untreated group.
Each bar represents mean value (SD) of two different CAF donors, each
measured in triplicates. Student’s t-test value (*p<0.05).
Discussion
High-dose radiotherapy is increasingly being used in the clin-
ics for treatment of solid malignancies, and this approach is
associated not only with higher rates of loco-regional tumor
control but also with the induction of secondary effects which
influence therapy outcomes, such as changes in the vasculature
and the immune status of tumors (4). However, the effects of
radiation in key non-malignant cellular components of tumors
have not received much attention. In this study, we aimed at
uncovering the responses of tumor fibroblasts (CAFs) to HD-RT
in relation to their function as regulators of tumor immunity.
Three main observations can be highlighted from our study:
(i) CAFs display a powerful immunosuppressive effect over T-
cells, affecting both their function and migration rates; (ii) Nei-
ther HD-RT (1 18Gy) nor LD-RT (4 2Gy) is influencing the
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FIGURE 5 | Levels of immunosuppressive factors expressed in
supernatants of irradiated and non-irradiated CAF cultures. Levels of
immunosuppressive factors were measured by ELISA in conditioned medium
obtained from irradiated (18Gy) or non-irradiated (0Gy) CAF cultures. Each
bar represents meanSD of five different CAF donors from triplicate
experiments. ND, non-detected.
immunosuppressive functions of CAFs in vitro; and (iii) HD-RT
do not ignite ICD responses in CAFs.
Ionizing radiation modifies the tumor cell phenotype and
induces a tumor microenvironment that fosters innate and adap-
tive immune responses. At high doses, RT enhances tumor cell
injury and the release of proteins from inside the cells that
may alert the immune system. Concomitantly, HD-RT has been
associated with an increased surface expression of molecules by
tumor cells with immuno-modulating functions such as MHC
class I (45), ICAM-1, and the death receptor CD95 (46). On
the other hand, the activation status of inflammatory cells may
also be altered by radiation. Previous reports have suggested that
HD-RT favors the presence of type-2 macrophages with tolero-
genic functions, an effect associated with induction of immune
inhibitory molecules such as COX-2/PGE-2 (47). Whereas low-
dose irradiationmay redirectmacrophage differentiation from the
immunosuppressive state (type-2) to one that enables recruitment
of cytotoxic T-cells. Also, LD-RT has been shown to reduce the
production of reactive oxygen species and the activity of inducible
nitric oxide synthase by activated macrophages (48). Despite
the accumulating literature on the immunomodulatory effects
exerted by radiotherapy on the different cellular components in
malignancies, it remains unexplored how CAFs respond to radio-
therapy in regard to their important immunoregulatory roles.
In this work, we disclose that neither HD-RT, given as a single
fraction of 18Gy (clinically relevant dose in the context of SABR),
nor LD-RT, given as fractionated small doses (clinically relevant in
the context of conventional RT), is altering the immunoinhibitory
functions of CAFs.
The role of CAFs as immunoregulatory cells in tumors has been
studied to some extent in the past; however a general consensus on
the ultimate role played by these cells on local immunoreactions is
still lacking. Animal studies, like the ones by Kraman et al. (32) or
Liao et al. (49), highlighted already some years ago the important
role played by CAFs as crucial immunosuppressive cells, empha-
sizing the capacity of CAFs to influence immune polarization
toward a permissive, tumor-promoting microenvironment (32,
49). However, this view has later on been challenged by other
studies, which demonstrate CAF-mediated anti-tumor immune
responses in pancreas cancer (50), or a bidirectional role observed
with CAFs from non-small cell lung cancer in coculture exper-
iments with tumor-associated T-cells (42). To ascertain the role
played by CAFs as immunoregulators in our system, we initially
ran T-cell proliferation assays in coculture conditions with CAFs.
Our results showed a very clear and reproducible inhibitory effect
exerted by CAFs. Of note, this effect was basically identical for
both non-irradiated and irradiated CAFs, and independent on the
radiation dose and fractionation schedules applied. Additionally,
we observed that the effect is primarily mediated via release of
paracrine signals, since very similar results were reproduced by
only using the CM. Our in vitro functional studies also included
effector cytokine expression by T-cell assays andmigration assays.
Both sets of experiments reinforced the initial observation on
CAF-mediated immunosuppressive actions, and bring out the fact
that CAFs are able to down-regulate both the activation status
and the migration (or recruitment) of PHA-activated T-cells. Of
importance, in all functional assays, radiation exposure of cells did
not contribute to variations on the observed effects.
Through the production of miscellaneous soluble signals
including chemokines, cytokines, and extracellular matrix
molecules, CAFs are able to influence the trafficking
and activation status of T-lymphocytes. Acknowledged
immunosuppressive molecules produced by CAFs include
TGF-β1 (34), PGE2, IDO (33), or tenascin-C. All these molecules
exert a direct negative effect on the acquisition and the expression
of T-cell effector functions. Additionally, some of these factors
are also known to deactivate or suppress NK cells. Moreover,
CAFs may contribute to the accumulation and/or differentiation
of regulatory T-cells in tumors through the expression of TGF-β
(51) or the chemokine CCL5/RANTES (52). In our study,
we have checked the expression of some of the mentioned
proteins as well as other recognized immunosuppressive
molecules by quantitative approaches. Signaling molecules
such as IL-4, TGF-β, and PGE2 could be readily detected
in CAF cell culture supernatants; however, their expression
remained unchanged after exposure to a radiation-dose of 18Gy.
Additionally, the CAF secretome was analyzed by a proteomic
approach. Mass spectometry data put forward a list of more
than 260 proteins released by CAFs with immunomodulatory
functions. Interestingly, we identified several complement
components and also well-known inflammatory regulators
such as IL-6, prostaglandin H2, and macrophage colony-
stimulating factor (CSF-1). Of note, immunomodulators such
as pentraxin and galectin-3 could be identified in the culture
media of both CAFs and iCAFs. These molecules represent
interesting leads for further investigation of the mechanism
behind the CAF-mediated immunoregulatory actions. The
overall findings on soluble signal molecules are in agreement
with our observations in the functional assays no differences
were found on immunosuppressive functions between irradiated
and non-irradiated cells. However, it is still undefined which
CAF-derived factor, or combination of factors, is ultimately
responsible for the inhibitory effect observed on T-lymphocytes.
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FIGURE 6 | Analyses of CAF secretome by mass spectrometry.
Conditioned medium from CAFs and iCAFs concentrated by ultrafiltration
was analyzed for total protein content by LC-MS/MS proteomics. In this
figure, only proteins relevant in the context of immunoregulation and
expressed by most CAF donors are represented. Logarithms (log2) of Label
free quantification (LFQ) intensities were calculated, and average values for
irradiated (n= 6) and control (n= 6) samples were presented with standard
deviations.
HD-RT is associated with increased tumor-antigen expression
and the induction of necrotic forms of tumor cell death. Conse-
quently, intracellular proteins naturally occurring in the nucleus,
organelles, or the cytoplasm are released. Such molecules operate
as damage-associated molecular patterns (DAMPs) or alarmins
(53), and have the potential to prime the immune system and
mount an immune attack. This phenomenon is now defined as
ICD (20, 54). Well-studied danger signals include release of the
DNA binding protein HMGB-1, cytosolic ATP, the stress factor
heat-shock protein 70, and the plasma membrane translocation
of endoplasmic reticulum-associated calreticulin. Again, existing
literature on ICD-responses in the context of radiation have essen-
tially considered responses from dying tumor cells; however, no
attention has been paid to the contribution of CAFs in this matter.
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FIGURE 7 | Irradiated CAFs do not release immunogenic cell death
signals. (A) Relative levels of extracellular ATP in irradiated (118Gy) CAF
cultures were measured at 1, 6, and 24 h post-irradiation. Results were
compared with levels of ATP released by non-irradiated cells (0Gy) and with a
positive control (CTR+) obtained after cell lysis. There were no significant
differences between ATP released by irradiated and non-irradiated cells at any
time point. Bars represent mean valueSD from two different CAF donors.
Horizontal bar is shown for comparison of values. (B) Expression of HMGB1 in
CAF supernatants was analyzed from cells representing 1, 6, 24, and 120 h
after irradiation (18Gy) by Western blot, and compared with levels of HMGB1
released by non-irradiated cells at the indicated time point. Results show no
detectable release of HMGB1. Data are from one representative experiment
out of two independent experiments. Intracellular HMGB1 measured in whole
cell lysates was used as a positive control.
Here, we report for the first time that HD-RT does not trigger
ICD in human CAFs, as no release of ATP or HMGB-1 could be
measured in CAF-CM at any time point.
Still, much of the complex interactions between stromal fibrob-
lasts and the different arms of the immune system in cancers
remain unknown. By using fresh human material, we show
here that CAFs from NSCLC exert powerful immunosuppressive
effects on T-lymphocytes. In our laboratory, we are currently
making efforts to track down the CAF-derived soluble factors
responsible for this effect. Of importance, HD-RT, which is able
to induce cellular senescence and other important phenotypic
changes on CAFs, do not affect the immunoregulatory actions of
these cells. Moreover, HD-RT, which is known to induce ICD-
responses in dying tumor cells, does not trigger ICD in CAFs.
We present here important new clues that help us understand the
overall responses of tumor constituents to radiotherapy, and we
believe that our data should be taken into account at the time of
considering HD-RT as an immunoadjuvant in clinical settings.
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